SEC Filing Summary: Hemispherx Biopharma, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on May 27, 2014, reporting an event that occurred on May 13, 2014. The company is a biopharmaceutical entity incorporated in Delaware.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance.
Material Changes
On May 13, 2014, the United States Patent Office issued U.S. Patent No. 8,722,874 to Hemispherx Biopharma, Inc. The patent is titled "Double-Stranded Ribonucleic Acids with Rugged Physiochemical Structure and Highly Specific Biologic Activity" and lists Carter, et al. as inventors.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors. The primary disclosure is the successful acquisition of intellectual property rights.
Key Facts for Investor Verification
- Verify the scope and commercial applicability of U.S. Patent No. 8,722,874.
- Confirm the status of the press release attached as Exhibit 99.1 for additional details on the patent's impact.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.